Table 2. Clinical characteristics of the cases and the controls.
AKY (Discovery) | BBJ (Validation 1) | BBJ2 (Validation 2) | |||||
(%) | (%) | (%) | |||||
Controls | |||||||
Number of samples | 749 | 5236 | 1045 | ||||
Mean age [s.d.] | 68.6 | [7.5] | 68.4 | [10.3] | 70.8 | [6.8] | |
Serum PSA level | N/A | N/A | |||||
PSA≤1 | 433 | (41.4) | |||||
PSA1–10 | 575 | (55.0) | |||||
PSA≥10 | 37 | ( 3.5 ) | |||||
Cases | |||||||
Number of samples | 689 | 2950 | 344 | ||||
Mean age [s.d.] | 67.8 | [7.1] | 74.0 | [7.0] | 71.3 | [6.7] | |
Serum PSA level | |||||||
PSA≤10 | 362 | (52.5) | 513 | (17.4) | 211 | (61.3) | |
PSA10–20 | 150 | (21.8) | 271 | (9.2) | 60 | (17.4) | |
PSA≥20 | 155 | (22.5) | 400 | (13.6) | 73 | (21.2) | |
Missing data | 22 | (3.2) | 1766 | (59.9) | 0 | (0.0) | |
Tumor stage | N/A | ||||||
T0 | 7 | (1.0) | 6 | (0.2) | |||
T1 | 226 | (32.8) | 224 | (7.6) | |||
T2 | 225 | (32.7) | 345 | (11.7) | |||
T3 | 133 | (19.3) | 200 | (6.8) | |||
T4 | 14 | (2.0) | 32 | (1.1) | |||
Missing data | 84 | (12.2) | 2143 | (72.6) | |||
Nodal stage | N/A | ||||||
N0 | 590 | (85.6) | 742 | (25.2) | |||
N1 | 25 | (3.6) | 30 | (1.0) | |||
Missing data | 74 | (10.7) | 2178 | (73.8) | |||
Metastasis data | N/A | ||||||
M0 | 585 | (84.9) | 727 | (24.6) | |||
M1 | 56 | (8.1) | 43 | (1.5) | |||
Missing data | 48 | (7.0) | 2180 | (73.9) | |||
Clinical stage | N/A | N/A | |||||
A | 3 | (0.4) | |||||
B | 458 | (66.5) | |||||
C | 120 | (17.4) | |||||
D | 95 | (13.8) | |||||
Missing data | 13 | (1.9) | |||||
Gleason score | N/A | ||||||
GS≤6 | 138 | (20.0) | 755 | (25.6) | |||
GS7 | 238 | (34.5) | 622 | (21.0) | |||
GS≥8 | 152 | (22.1) | 114 | (3.9) | |||
Missing data | 161 | (23.4) | 1459 | (49.5) | |||
High risk PC* | 302 | (43.8) | N/A | N/A | |||
Non-high risk PC | 280 | (40.6) | |||||
Missing data | 107 | (15.5) |
AKY: Akita-Kyoto cohort, BBJ: Biobank Japan cohort, BBJ2: Biobank Japan cohort 2.
High risk PC fulfills either of the following criteria; PSA≥20, or Gleason Score≥8, or clinical stage≥C.